Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR).

Full DD Report for EIGR

You must become a subscriber to view this report.


Recent News from (NASDAQ: EIGR)

Rounds Report: Eiger Moved Northbound While Spectrum Rallied Strongly Due To ADVANCE Trial Results
You don’t make money when you buy stocks. And you don’t make money when you sell stocks. You make money by waiting.- Stellar Value Investor (Mohnish Pabrai) Trading Analytics Welcome to this edition of Integrated BioSci Rounds Report for May 17, 2018. As usual, weȁ...
Source: SeekingAlpha
Date: May, 18 2018 02:15
Reader Inquiry: Is There Further Upside Ahead For Eiger BioPharmaceuticals?
Shares of Eiger BioPharmaceuticals ( EIGR ) have surged over 80% during the past five days. On the other hand, the stock has risen by 65% since my original article from March of last year. I first mentioned the stock in ROTY Live Chat on April 25th when I came across this CBS report wit...
Source: SeekingAlpha
Date: May, 18 2018 01:05
After Hours Gainers / Losers (05/17/2018)
Top gainers:   QTNT   +12.1% .  AFSI +6.1% . EIGR   +3.5% . DRNA +3.0% . TIVO   +2.0% . More news on: Quotient Limited, AmTrust Financial Services, Inc., Eiger BioPharmaceuticals, Inc., Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 17 2018 17:35
Midday Gainers / Losers (05/17/2018)
Gainers: CARV +78% . CPSH +40% . EGY +24% . EIGR +20% . LOXO +18% . BZUN +17% . BDSI +17% . RTTR +16% . ESND +15% . WWE +15% . More news on: Carver Bancorp, Inc., CPS Technologies Corp., VAALCO Energy, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 17 2018 12:40
Healthcare - Top 5 Gainers / Losers as of 12:20 AM (05/17/2018)
Gainers : LOXO +19% . RTTR +18% . SPPI +17% . EIGR +16% . BDSI +15% . More news on: Loxo Oncology, Ritter Pharmaceuticals, Spectrum Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 17 2018 12:21
Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data
Analysis focus: LOXO Loxo Oncology (LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (...and so on), is up strongly “following...
Source: SeekingAlpha
Date: May, 17 2018 12:00
Eiger expands license agreement with Merck for Lonafarnib and collaboration with Progeria Research Foundation
Eiger BioPharmaceuticals (NASDAQ: EIGR ) has expanded its licensing agreement with Merck, to include rights to develop farnesyltransferase inhibitor lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), a rare and fatal genetic condition characterized by ...
Source: SeekingAlpha
Date: May, 16 2018 08:57
Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals
PEABODY, Mass. , May 16, 2018 /PRNewswire/ -- The Progeria Research Foundation (PRF) announced a collaboration and supply agreement with Eiger BioPharmaceuticals for the development and pursuit of U.S. Food and Drug Administration review and potential approval of lonafarnib for the t...
Source: PR Newswire
Date: May, 16 2018 08:00
Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
PALO ALTO, Calif. , May 16, 2018 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has expanded its licensing agreement with Merck, known as MSD outside t...
Source: PR Newswire
Date: May, 16 2018 08:00
Eiger: A Hidden Gem Creates A Lot Of Upside Potential
Investment Summary And Conclusion The consensus view is that Eiger BioPharmaceuticals ( EIGR ) is a company with four pipeline candidates in three diseases. The company has Lonafarnib and PEG IFN Lambda for HDV (Hepatitis Delta Virus), Exendin 9-39 for PBH (Post bariatric Hypoglycemia), and ...
Source: SeekingAlpha
Date: May, 14 2018 11:04

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-2214.5013.7014.5013.45388,907
2018-05-2114.5514.6514.9514.30294,111
2018-05-1818.0013.9018.0013.351,327,316
2018-05-1712.4016.8017.34511.701,325,749
2018-05-1611.4011.8511.9511.25229,704

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2253,610136,31539.3280Short
2018-05-2120,96781,91225.5970Cover
2018-05-18158,596497,94431.8502Cover
2018-05-17283,610466,65660.7750Short
2018-05-1632,31566,28048.7553Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on EIGR.


About Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)

Logo for Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $105,265,990 - 05/11/2018
  • Issue and Outstanding: 10,526,599 - 03/02/2018

 


Recent Filings from (NASDAQ: EIGR)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: EIGR)

Daily Technical Chart for (NASDAQ: EIGR)


Stay tuned for daily updates and more on (NASDAQ: EIGR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: EIGR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in EIGR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of EIGR and does not buy, sell, or trade any shares of EIGR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/